Standard BioTools Inc.

Standard BioTools Inc. develops, manufactures, and sells instrumentation, consumables, and services for scientists and biomedical researchers, primarily to support therapeutic development. The company operates through two segments: Proteomics and Genomics. Its proteomics and genomics offerings include instruments, consumables, and assays for clinical and diagnostic uses. Key platforms include the SomaScan platform, which enables simultaneous measurement of thousands of proteins to provide insights into biological processes and disease mechanisms; the CyTOF technology platform, which uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; the Hyperion spatial biology platform for high-dimensional molecular and proteomic analysis while preserving tissue spatial context; and the Biomark X9 system for high-throughput genomics in quantitative polymerase chain reaction applications.

Standard BioTools Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol LAB. The company's shares are traded in United States Dollars (USD). As a US-based company, its stock is denominated in USD, and investors typically trade it on the Nasdaq exchange during regular market hours.

Standard BioTools Inc. operates in the Healthcare sector and is classified under the Medical Devices industry. This means the company is involved in developing and manufacturing medical devices and related technologies used in healthcare and biomedical research. Specifically, its products are designed for proteomics and genomics applications, helping researchers study proteins and genes to advance therapeutic development. The Medical Devices industry includes companies that produce instruments, consumables, and services for diagnostic, clinical, and research purposes.

Standard BioTools Inc. is headquartered in Boston, Massachusetts, United States. The company serves customers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its products are sold to academic research institutions, translational research and medicine centers, cancer centers, clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. The company sells its instruments and consumables for research use only, not for diagnostic or clinical purposes.

Standard BioTools Inc. offers several key technology platforms. The SomaScan platform enables researchers to measure thousands of proteins simultaneously, providing deep insights into biological processes and disease mechanisms. The CyTOF technology platform uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities for high-dimensional cellular analysis. The Hyperion spatial biology platform allows analysis of tissue organization while preserving spatial context for high-dimensional molecular and proteomic studies. Additionally, the Biomark X9 system redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company also has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.